...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current opinion in gastroenterology >Targeting tumor necrosis factor-alpha in inflammatory bowel disease: why, how, and when?
【24h】

Targeting tumor necrosis factor-alpha in inflammatory bowel disease: why, how, and when?

机译：针对炎症性肠病中的肿瘤坏死因子-α：为什么，如何以及何时？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A large proportion of patients with inflammatory bowel disease require more effective therapy, especially for the prevention of disease relapse. Recent therapeutic advances have focused on biologicals (monoclonal antibodies, therapeutic peptides, antisense oligonucleotides) that aim to neutralize specific proinflammatory proteins. This has proved successful for the anti-TNF-alpha antibody infliximab in patients with Crohn disease, but recent studies failed to demonstrate the efficacy of different anti-TNF-a strategies. Therefore, it seems essential to fully comprehend the molecular mechanisms of such compounds. An exciting development has been the association between drug efficacy and the induction of apoptosis in apoptosis-resistant lamina propria T cells in Crohn disease. Furthermore, TNF-a can also be targeted by "small molecules" to circumvent certain disadvantages of biologicals such as the nonoral route of administration, the potential immunogenicity, and the high costs of treatment. Several of these developments will certainly be relevant for designing future anti-TNF-a based strategies.
机译：炎性肠病患者中有很大一部分需要更有效的治疗，尤其是对于预防疾病复发。最近的治疗进展集中在旨在中和特定促炎蛋白的生物学物质（单克隆抗体，治疗性肽，反义寡核苷酸）上。事实证明，这对于克罗恩病患者的抗TNF-α抗体英夫利昔单抗是成功的，但是最近的研究未能证明不同抗TNF-α策略的疗效。因此，充分理解此类化合物的分子机制似乎至关重要。激动人心的发展是在克罗恩病中，在抗凋亡的固有层T细胞中，药物功效与诱导凋亡之间的联系。此外，TNF-α还可以被“小分子”靶向以规避生物学的某些缺点，例如非口服给药途径，潜在的免疫原性和高昂的治疗费用。这些发展中的一些肯定与设计未来基于抗TNF-a的策略有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号